May. 14 at 11:54 AM
$CLRB PR-Update – Cash Secured, Data is Ace, NDA Filing Incoming! My take:The 12-month CLOVER-WaM results are rock solid. A 61.8% MRR and 98.2% Disease Control Rate in r/r WM is a massive win, especially since it holds up in the tough post-BTKi population.Fully Funded: That
$140M financing from top-tier healthcare funds (Nantahala, Balyasny, etc.) is a game-changer. It extends the runway into 2027, covering the confirmatory Phase 3 and the path to commercialization.The Path to NDA: Cellectar is now officially moving toward the Accelerated Approval filing. The data aligns perfectly with FDA expectations. My Bottom Line: I’m incredibly excited for the webcast (Teco). I’ll be listening closely for the exact NDA filing timeline. If management provides a tight window, we have our next major catalyst. The heavy institutional backing tells you everything you need to know about the smart money's conviction.
